⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 26, 2024CancersOpen Access

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer

Aakash Desai Tadana A. Vázquez Keishla M. Arce Marcelo Corassa Philip C. Mack Jhanelle E. Gray Bruna Pellini

View Full Paper

Ask AI

Bookmark

Share

Abstract

Circulating tumor DNA (ctDNA) offers a new paradigm in optimizing treatment strategies for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Its potential spans early-stage disease, influencing adjuvant therapy, to advanced disease, where it aids in identifying genomic markers and resistance mechanisms. This review explores the evolving landscape of utilizing liquid biopsies, specifically circulating tumor DNA (ctDNA), in the management of NSCLC with

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Desai et al. (2024) studied this question.

synapsesocial.com/papers/68e777acb6db6435876eca4f https://doi.org/10.3390/cancers16050940

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the ClinicianReview · 2017 · 23 citations
2Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detectionReview · 2026 · 1 citations
3Circulating tumor DNA: An alternative to tissue biopsy for detecting epidermal growth factor receptor mutation in non-small cell lung cancerOriginal Research · 2026
4373P Circulating tumor DNA as a predictive biomarker for early-stage NSCLCOriginal Research · 2026
5Genomics in Lung Cancer: A Scoping Review of the Role of ctDNA in Non-Advanced Non-Small-Cell Lung Cancer in the Prediction of Prognosis After Multimodality Therapeutic Approaches2025